Daiichi Sankyo to pay Merck $170 million for cancer test drug rights
Daiichi Sankyo will pay Merck & Co. Inc., $170 million upfront to bag commercialization and development rights of the latter’s test drug for.
Drugs
Health
Pharma
Drugs
Health
Pharma
Scientists develop potential compound to neutralise flesh-eating bacteria
A family of antimicrobial compounds can neutralise necrotising fasciitis, a deadly bacterial skin infection that is also known as flesh-eating disease, when tested.
Drugs
Health
Pharma
New cardiovascular risk calculator may impose a burden on 16 million US citizens
HQ Team August 6, 2024: A new cardiovascular disease risk calculator may render 16 million US citizens ineligible for preventive therapy if the.
Drugs
Health
Pharma
GenX faces a higher risk of 17 cancer types than older generation
Seventeen types of cancer are common in US millennials and the incidence rate for some forms is two to three times higher in.
Drugs
Health
Pharma
WHO warns on drug-resistant Klebsiella Pneumonie spread
HQ Team August 4, 2024: The WHO has warned about the rising global incidence of hypervirulent and multi-resistant Klebsiella Pneumoniae (hvKp) infections. The.
Drugs
Health
Pharma
Backyard species in US gets Covid-19 through human-to-animal spread
The SARS-CoV-2 virus was detected in six backyard species in the southeastern US state of Virginia with unique viral mutations with lineages closely.
Drugs
Health
Pharma
Wegovy gets EU regulator backing on lowering heart risks in obese people
The European Medicines Agency has backed Novo Nordisk’s Wegovy to expand the weight-loss drug’s application to lower heart risks and strokes in non-diabetic.
Drugs
Health
Pharma
Biogen, Sage halt tremor trial after ‘disappointing’ oral drug results
An oral investigational drug jointly developed by Biogen Inc., and Sage Therapeutics Inc., failed to stop essential tremors in patients, forcing the companies.
Drugs
Health
Pharma
Merck’s experimental RSV injection lowers infections in infants
The US-based Merck and Co.’s investigational medicine to protect infants from respiratory syncytial virus (RSV) disease has resulted in lowering infections, according to.
Drugs
Health
Pharma
US-based Agilent Technologies to acquire Canada’s Biovectra for $925m
HQ Team July 23, 2024: Agilent Technologies Inc., will acquire Canada-based Biovectra, a contract development and manufacturing company, for $925 million, according to.